Acta clinica Croatica, Vol. 40 No. 1, 2001.
Recenzija, Prikaz slučaja
Plasmapheresis and Specific Immunoadsorption in the Treatment of Myasthenia Gravis
Petar Kes
Vanja Bašić-Kes
Sažetak
Myasthenia gravis is an antibody-mediated autoimmune disease in which circulating acetylcholine receptor (AChR) antibodies have been identified that bind to the receptor sites in voluntary muscles, thereby damaging and blocking the receptors. Selective removal of the blocking antibody by plasmapheresis or specific immunoadsorption provides important methods in the treatment of patients with myasthenia gravis. Novel immunoadsorbent columns have been developed especially for the treatment of patients with myasthenia gravis, using a specific affinity ligand (Torpedo 183-200, a synthetic peptide) to remove the blocking antibody. This immunoadsorbent produced specific removal of the blocking antibody without reducing other plasma proteins. Clinical improvement was observed in 78% of myasthenia gravis patients. There were no adverse effects.
Ključne riječi
Myasthenia gravis, therapy; Plasmapheresis
Hrčak ID:
14847
URI
Datum izdavanja:
1.3.2001.
Posjeta: 3.331 *